Zevalin and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Zevalin (ibritumomab tiuxetan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Rituxan, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Nosebleed when taking Zevalin. It is created by eHealthMe based on reports of 2,256 people who have side effects when taking Zevalin from the FDA, and is updated regularly.

What is Zevalin?

Zevalin has active ingredients of ibritumomab tiuxetan. eHealthMe is studying from 2,258 Zevalin users. Check the latest studies of Zevalin.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 20, 2026

2,256 people reported to have side effects when taking Zevalin.
Among them, 18 people (0.8%) have Nosebleed.

Among these 18 people:

How long have people been on Zevalin when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Zevalin? *

female: 100 %
male: 0.0 %

What is the age of people who have Nosebleed when taking Zevalin? *

What are other drugs people take besides Zevalin? *

What are other side effects people have besides Nosebleed? *

Thrombocytopenia (decrease of platelets in blood): 10 people, 55.56%
Head Injury: 10 people, 55.56%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 7 people, 38.89%
Bone Marrow Failure: 7 people, 38.89%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 5 people, 27.78%
Bleeding Into The Skin: 5 people, 27.78%
Herpes Zoster: 4 people, 22.22%
Purpura (purplish discoloration of the skin): 4 people, 22.22%
Drug Toxicity: 3 people, 16.67%
White Blood Cell Count Decreased: 3 people, 16.67%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 12 people, 66.67%
Metastasis (spreadable cancer to other organ from origin): 1 person, 5.56%
Metastases To Bone (cancer spreads to bone): 1 person, 5.56%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 5.56%
Lymphoma (cancer that begins in immune system cells): 1 person, 5.56%
Carbohydrate Antigen 15-3 Increased: 1 person, 5.56%
Breast Cancer Metastatic: 1 person, 5.56%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Zevalin and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zevalin:

Zevalin (2,258 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Zevalin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibritumomab tiuxetan (the active ingredients of Zevalin) and Zevalin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.